Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AMR-001
NBS10 · 1 trial · 1 indication
The primary endpoint includes the occurrence of AE's, SAE's and Major Adverse Cardiac Events (MACE) and the assessment of myocardial perfusion measured by quantitative gated SPECT MPI specifically looking at resting total severity score.
| Arm | Type | Description |
|---|---|---|
| NBS10 | EXPERIMENTAL | active treatment - CD34+ cells |
| placebo | PLACEBO_COMPARATOR | matching placebo |
| Name | Type | Description |
|---|---|---|
| NBS10 | BIOLOGICAL | dosage = 10 or more million CD34+ cells via intracoronary infusion |
| placebo | OTHER | matching placebo |
Inclusion Criteria: 1. Age 18 years or older. 2. Acute ST elevation myocardial infarction meeting ACC/AHA criteria, with symptoms of chest pain within 3 days of admission. Criteria include (ST elevation \> 1mm in limb leads or 2 mm in two or more precordial leads, and increased levels of troponin, ...
NBS10 is an investigational monoclonal antibody developed by Lisata Therapeutics, Inc. (ticker LSTA) for the treatment of ST Segment Elevation Myocardial Infarction, a type of heart attack. It is a Phase 2 cardiovascular therapy and is not approved for commercial use.
NBS10 is being developed for use after ST Segment Elevation Myocardial Infarction, commonly known as a heart attack. The goal is to support cardiac repair following the event. It remains investigational and has not been approved for any indication.
NBS10 targets CD34, a cell surface protein. CD34 is a marker found on certain progenitor cells. By binding CD34, NBS10 is designed to interact with these cells as part of its therapeutic approach in cardiovascular repair after myocardial infarction.
NBS10 is being developed by Lisata Therapeutics, Inc., which trades under the ticker LSTA. The company is responsible for the clinical program evaluating NBS10 in cardiovascular disease.
NBS10 is in Phase 2 clinical development. It is an investigational therapy and has not received FDA approval. The Phase 2 trial has been completed, and no active trials are currently listed for this asset.
NBS10 has been studied in one completed Phase 2 trial, NCT01495364, titled NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction. The randomized, double-blind, placebo-controlled trial enrolled 195 participants in the United States.
Yes, NBS10 is also known as AMR-001. The Phase 2 trial NCT01495364 used both names in its title, confirming they refer to the same investigational monoclonal antibody developed by Lisata Therapeutics for ST Segment Elevation Myocardial Infarction.